AZD-9574

目录号: GC64099纯度: >98%

AZD-9574是一种新型的、具有血脑屏障通透性的PARP1抑制剂，AZD-9574在SSB位点选择性抑制PARP1。

Cas No.: 2756333-39-6

规格	价格	库存	数量
1mg	¥945.00	现货	1
5mg	¥2,240.00	现货	1
10mg	¥3,360.00	现货	1
10mM (in 1mL DMSO)	¥2,111.00	现货	1

电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例

Nature
641, 529–536 (2025)
Nature
628, 630–638 (2024)
Nature
632, 686–694 (2024)
Nature
618, 1017–1023 (2023)
Nature
610, 366–372 (2022)
Cell
187(9):2288-2304 (2024)
Cell
183(7):1867-1883 (2020)
Science
388(6745) (2025)
Science
387(6739) (2025)
Science
387(6734) (2025)
Cell Research
35, 97–116 (2025)
Cell Research
34, 683–706 (2024)
Cell Research
33, 273–287 (2023)
Cell Research
33, 546–561 (2023)
Cell Research
33, 904–922 (2023)
Cell Research
31, 1291–1307 (2021)

产品描述 Description

AZD-9574 is a novel, blood-brain barrier permeable PARP1 inhibitor that selectively inhibits PARP1 at single-strand break (SSB) sites^[1-2]. AZD-9574 can be used in research related to breast cancer and advanced solid malignancies^[3-4].

In vitro, AZD-9574 (0.1nM–40µM) was incubated with homologous recombination repair-deficient (HRD) cancer cells (such as MDA-MB-436, DLD-1 BRCA2-/-, and SKOV3 BRCA2-/- cells) for 72 hours to 13 days. AZD-9574 significantly inhibited cancer cell colony formation, increased γH2AX signaling, induced G2-M phase cell cycle arrest, and enhanced the synergistic anti-tumor effects of TMZ^[5].

In vivo, AZD-9574 (3mg/kg/day) was orally administered to C57BL/6 mice bearing H3K27M diffuse midline glioma (using H3K27MPP cells) in combination with 2Gy radiotherapy (administered 1 hour before each radiation fraction, for 6 consecutive days). AZD-9574 significantly prolonged the overall survival of the mice and enhanced intratumoral NK cell infiltration and activation^[6]. AZD-9574 (0.6–3mg/kg) was administered once daily by oral gavage for 7 consecutive days to mouse models bearing patient-derived (H3F3A K27M, TP53R248W, ATRX-deficient) or genetically engineered (H3F3A K27M; Trp53⁻/⁻) diffuse midline glioma orthotopic xenografts. AZD-9574 significantly extended the survival of these mice and effectively inhibited the growth and recurrence of orthotopic tumors within the mouse brain^[7].

References:
[1] Johannes JW, Balazs AYS, Barratt D, et al. Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor. J Med Chem. 2024 Dec 26;67(24):21717-21728.
[2] Zhou X, Chen K. Discovery of novel radioligand [18F]AZD9574 for selective imaging of PARP1 in the CNS. Acta Pharm Sin B. 2025 Oct;15(10):5489-5490.
[3] Lynce F, Lin NU. From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors. Clin Cancer Res. 2024 Apr 1;30(7):1217-1219.
[4] Patel JS, Zhou X, Chen J, et al. A novel 18 F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1. bioRxiv. 2025 Nov 3:2025.11.01.686021.
[5] Guo Y, Li Z, Parsels LA, et al. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro Oncol. 2025 Sep 17;27(8):2129-2146.
[6] Staniszewska AD, Pilger D, Gill SJ, et al. Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. Clin Cancer Res. 2024 Apr 1;30(7):1338-1351.
[7] Chen X, Zhang S, Yang L, et al. Zeaxanthin dipalmitate-enriched wolfberry extract improves vision in a mouse model of photoreceptor degeneration. PLoS One. 2024 May 20;19(5):e0302742.

AZD-9574是一种新型的、具有血脑屏障通透性的PARP1抑制剂，AZD-9574在SSB位点选择性抑制PARP1^[1-2]。AZD-9574可用于乳腺癌和晚期实体恶性肿瘤的相关研究^[3-4]。

在体外，AZD-9574（0.1nM-40μM）孵育具有同源重组修复缺陷（HRD）的癌细胞（如MDA-MB-436、DLD-1 BRCA2-/-、SKOV3 BRCA2-/-细胞）72小时至13天，AZD-9574显著抑制癌细胞克隆形成、增加γH2AX信号、诱导G2-M期细胞周期阻滞，并增强TMZ的协同抗肿瘤效应^[5]。

在体内，AZD-9574（3mg/kg/day）口服处理携带H3K27M弥漫性中线胶质瘤（H3K27MPP细胞）的C57BL/6小鼠（与2Gy放疗联合使用，放疗前1小时给药，持续6天），AZD-9574显著延长小鼠的总体生存期并增强瘤内NK细胞的浸润与激活^[6]。AZD-9574（0.6–3mg/kg）每日一次灌胃给药，连续处理携带患者来源（H3F3A K27M, TP53R248W, ATRX缺失）或基因工程（H3F3A K27M; Trp53⁻/⁻）的弥漫性中线胶质瘤原位移植瘤小鼠模型7天，AZD-9574显著延长了小鼠的生存期，并有效抑制了小鼠大脑内原位肿瘤的生长与复发^[7]。

实验参考方法 Experimental Reference Method

Cell experiment [1]:
Cell lines	A549 (human lung carcinoma cell line, PARP1+/+/PARP2+/+), A549 PARP1-/- (isogenic knockout), A549 PARP2-/- (isogenic knockout), DLD-1 (human colorectal carcinoma cell line), DLD-1 BRCA2-/- (isogenic knockout), MDA-MB-436 (human breast cancer cell line, BRCA1 mutant), SKOV3 (human ovarian carcinoma cell line), SKOV3 BRCA2-/- (isogenic knockout), UWB1.289 (human ovarian carcinoma cell line, BRCA1 mutant), SJ-G2 (human glioblastoma cell line), GBM39 (human glioblastoma PDX cell line).
Preparation Method	Cell lines were maintained as per standard conditions. For PARylation assays, cells were treated with AZD-9574 at increasing doses. For colony formation assays, cells were seeded and incubated overnight, then treated with a titration of AZD-9574 (0.1nM to 40μM) for 8 to 13 days. For DNA damage and cell-cycle analysis, cells were treated with AZD9574 for 72 hours, with EdU added 1 hour before fixation.
Reaction Conditions	0.1nM to 40μM; 72 hours to 13 days.
Applications	AZD-9574 demonstrated potent, selective inhibition of PARP1 (over PARP2 and other PARPs) in biochemical and cellular assays. AZD-9574 inhibited PARylation in various cell lines with single-digit nanomolar IC₅₀ values. AZD-9574 induced PARP1 trapping on chromatin in a concentration-dependent manner but showed no PARP2 trapping. In HRD cancer cell lines (e.g., MDA-MB-436, DLD-1 BRCA2-/-), AZD-9574 exhibited potent anti-proliferative effects in colony formation assays, induced DNA damage (increased γH2AXSer139 foci), and caused cell-cycle arrest in the G2-M phase. Furthermore, AZD-9574 showed strong synergy with temozolomide (TMZ) in reducing cell viability in MGMT-methylated glioma cell lines (SJ-G2, GBM39).
Animal experiment [2]:
Animal models	C57BL/6 mice harboring syngeneic orthotopic H3K27M-mutant diffuse midline glioma (DMG) brainstem tumors (H3K27MPPcell line), immune competent mice
Preparation Method	Mice were treated with RT (2Gy, days 0-2 and 4-6) in combination with AZD-9574 (3mg/kg) administered by oral gavage 1 hour before each fraction of radiation and continued for 6 consecutive days.
Dosage form	3mg/kg; oral gavage (p.o.); Once daily for 6 days.
Applications	AZD-9574 in combination with RT significantly prolonged the median survival of mice bearing H3K27M mutant DMG tumors compared to RT alone (75 days vs. 42 days). The treatment enhanced intratumoral NK cell infiltration (frequency of CD3-NK1.1+CD45+cells) and increased NK cell activity, as evidenced by a higher proportion of TNF-α+, CD107a+, and IFN-γ+ NK cells. Furthermore, the combination therapy reduced tumor-associated macrophage numbers within the tumors.
References: [1] Staniszewska AD, Pilger D, Gill SJ, et al. Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. Clin Cancer Res. 2024 Apr 1;30(7):1338-1351. [2] Guo Y, Li Z, Parsels LA, et al. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro Oncol. 2025 Sep 17;27(8):2129-2146.

产品文档 Product Documents

Purity:>98%

COA SDS Data Sheet

化学性质Chemical Properties

CAS 号

2756333-39-6

分子式

C21H22F2N6O2

分子量

428.44 g/mol

溶解性

DMSO : 22.22 mg/mL (51.86 mM; ultrasonic and adjust pH to 4 with HCl); DMSO : 8.33 mg/mL (19.44 mM; ultrasonic and warming and heat to 60°C)

保存条件

Store at -20°C

General tips

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。

Shipping Condition

评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

质量 (Mass)

体积 (Volume)

浓度 (Concentration)

分子量 (MW)

g/mol